Download full-text PDF

Source
http://dx.doi.org/10.1159/000183248DOI Listing

Publication Analysis

Top Keywords

acute renal
4
renal failure
4
failure secondary
4
secondary sulfinpyrazone
4
sulfinpyrazone treatment
4
treatment myocardial
4
myocardial infarction
4
acute
1
failure
1
secondary
1

Similar Publications

Objectives: Serum galectin-3 (sGal-3) is a protein present in renal tubules and increases in experimental rodent models of acute kidney injury. The aim of this study was to compare sGal-3 concentrations in healthy cats and cats with ureteral obstruction (UO).

Methods: This was a retrospective study.

View Article and Find Full Text PDF

ERMP1 as a newly identified ER stress gatekeeper in chronic kidney disease.

Am J Physiol Renal Physiol

January 2025

Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

ERMP1 is involved in the Unfolded Protein Response (UPR) pathway in response to endoplasmic reticulum (ER) stress. Given the pivotal role of ER stress in the pathogenesis of acute and chronic kidney diseases, we hypothesized that ERMP1 could be instrumental in the development of renal injury. analysis of RNA sequencing datasets from renal biopsies were exploited to assess the expression of ERMP1 in the kidney under normal or pathological conditions.

View Article and Find Full Text PDF

Fulminant myocarditis (FM) is an acute, diffuse inflammatory myocardial disease characterized by abrupt onset and extremely rapid progression. Patients typically exhibit haemodynamic abnormalities that may lead to respiratory failure, liver and renal failure, and subsequent coagulopathy. Collectively, these complications significantly increase the risk of early mortality.

View Article and Find Full Text PDF

Finerenone: Will It Be a Game-changer?

Card Fail Rev

December 2024

Department of Nephrology and Renal Transplant Medicine, Max Super Speciality Hospital Saket, New Delhi, India.

Heart failure (HF) is a major contributor to hospitalisations and accounts for 7% of cardiovascular-related deaths, with patients who have chronic kidney disease and type 2 diabetes at heightened risk. Existing treatment guidelines inadequately address these comorbidities. Steroidal mineralocorticoid receptor antagonists (MRAs) are commonly used in HF with reduced ejection fraction but pose risks, such as hyperkalaemia and acute kidney injury.

View Article and Find Full Text PDF

Outcomes and risk factors of transported patients with extracorporeal membrane oxygenation: An ECMO center experience.

J Intensive Med

January 2025

Department of Critical Care Medicine, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Trauma Center, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China.

Background: Extracorporeal membrane oxygenation (ECMO) has been proven to be a support method and technology for patients with cardiopulmonary failure. However, the transport of patients under ECMO support is challenging given the high-risk technical maneuvers and patient-care concerns involved. Herein, we examined the safety of ECMO during the transport of critically ill patients and its impact on mortality rates, to provide more secure and effective transport strategies in clinical practice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!